Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Medical
EPIC: POSC
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Positron Corporation
www.positron.com

Positron Corporation offers innovative solutions through the production and distribution of molecular
imaging systems and radiopharmaceutical technologies.

Full Positron Corporation profile here
Pdf

Positron poised for growth in 2011

12th May 2011, 4:05 pm by Deborah Sterescu
Positron poised for growth in 2011

Positron Corp (OTCBB:POSC) said Thursday it expects increased sales in 2011, as the company looks to expand its product offerings.

The Indianapolis-based molecular imaging company, which specializes in the field of nuclear cardiology, sells Attrius positron emission tomography (PET) systems that can guide medical and interventional therapy in individual cardiac patients.

The company said that it expects to sell 30 such systems in 2011, provided the availability of radiopharmaceuticals for new accounts resume.

Positron added that it understands the recent reduction in the availability of Rubidium, the cardiac imaging agent, is temporary, and generators will be available as soon as August.
Radiopharmaceuticals, which feature radioactive isotopes, are used in the field of nuclear medicine as tracers in the diagnosis and treatment of many diseases.

In the first quarter, the company contracted three Attrius sales, with four systems pending financing. It also installed four in sold last year.

"Industry dynamics are incredibly favorable with a fundamental shift in the nuclear cardiac market that has created demand for PET systems and radiopharmaceuticals, as well as, the need for new and innovative distribution products and models for radiopharmaceuticals," said CEO Patrick G. Rooney.

Indeed, the company has developed a system, called PosiRx, that automates and simplifies the dose preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging.

In fact, Positron has already successfully completed testing and validation protocols for the new system, conducted by the New Mexico Center for Isotopes in Medicine at the University of New Mexico. It expects to install between 8 to 12 systems in the domestic market this year.

In addition, the company's Crown Point radiopharmaceutical manufacturing facility received the necessary regulatory licenses to produce radiochemicals, which will be available for sale in the second quarter.

Positron plans to seek the necessary FDA approval to sell radiopharmaceutical-grade products in the third quarter, reveneue which is expected to assist in subsidizing other projects.

“Positron has remained extremely focused on advancing and expanding its product offerings, which are more relevant than ever in the continually evolving field of nuclear cardiology," added Rooney.

 To accomplish its development goals, the company recently received financing, which allows it to fund operations, increase its sales force, expand marketing efforts and aggressively pursue research and development.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.